Mylan Pharmaceuticals, Inc. vs. Merck Sharp & Dohme Corp. et al.
Explore the PTAB proceeding IPR2020-00040 filed by Mylan Pharmaceuticals, Inc. on 2019-10-30. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.
Proceeding Overview
Proceeding Number
IPR2020-00040
Filing Date
2019-10-30
Accorded Filing Date
2019-11-14
Institution Decision Date
2020-05-12
Last Modified Date
โ
Proceeding Type
IPR
Termination Date
2021-05-07
Trial Status
Final Written Decision
Parties & Counsel
Petitioner
Mylan Pharmaceuticals, Inc.
Represented By
Malik, Jitendraet alPatent Owner / Respondent
Merck Sharp & Dohme Corp. et al.
Represented By
Fisher, Stanleyet alPatent Information
Tribunal & APJ Panel Intelligence
Tribunal
Patent Trial and Appeal Board (USPTO)
Technology Center
TC 1600 - Biotechnology & Organic Chemistry
Decisions Rendered
2 Total
Proceeding Status
Final Written Decision
Administrative Patent Judges (APJ Panel)
Board Decisions & Rulings (2)
Address and Attorney/Agent Information
Power of Attorney & Correspondence
Attorney / Agent Information
| Reg # | Name | Phone |
|---|---|---|
| 34398 | Mary Morry | +1 732-594-1935 |
| 36036 | John Todaro | +1 732-594-0125 |
| 36436 | Sylvia Ayler | +1 732-594-4909 |
| 36502 | Catherine Fitch | +1 732-594-4283 |
| 42068 | Dianne Pecoraro | +1 732-594-1249 |
| 42452 | Anna Cocuzzo | +1 -- |
| 42876 | Eric Meade | +1 732-594-1045 |
| 43039 | John Reilly | +1 732-594-6914 |
Global Patent Family Cross-Litigation Radar
CasLoc 360ยฐ Radar 2 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| ๐บ๐ธ United States | US 7,326,708 B2 Asserted | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 48,216,103 P | US Continuation / Sibling | View Official Patent → |
Sun Pharmaceutical Industries Ltd. et al. v. Merck Sharp & Dohme Corp. et al.
Dr. Reddy's Laboratories, Inc. et al. v. Merck Sharp & Dohme Corp. et al.
Teva Pharmaceuticals USA, Inc. v. Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp. v. Mylan Pharmaceuticals Inc.
Merck Sharp & Dohme Corp. v. Teva Pharmaceuticals USA, Inc.
Merck Sharp & Dohme Corp. v. Sun Pharmaceutical Industries Ltd.
Merck Sharp & Dohme Corp. v. Alvogen Pine Brook LLC
Merck Sharp & Dohme Corp. v. Watson Laboratories, Inc.
Merck Sharp & Dohme Corp. v. Sandoz Inc.
Standard Essential Patent (SEP) & FRAND Intelligence
5G SEP โข ETSI Declared High-Probability SEP ActionEssential standard specifications, SSO declaration status, and FRAND antitrust defense evaluation
Injunction Restrictions & FRAND Defense Leverage (CJEU Huawei v. ZTE Framework)
Permanent Injunction RestrictedAsserted by recognized SEP declarant. Under the CJEU Huawei v. ZTE test, injunctions are barred if the defendant qualifies as a willing licensee.